Archive | March, 2022

Digital RESI June Preliminary Agenda

24 Mar

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI returns June 7-9 with virtual panel discussions designed to engage early-stage entrepreneurs and life science investors on strategies for success in fundraising. These conversations explore topics that are relevant to the early-stage ecosystem and provide insight to founders seeking capital and channel partners.

In addition to some topics back by popular demand, new topics will be introduced, such as partnerships with small and mid-sized pharma and the intersection of healthcare IT and medtech. Additionally, there will be two new topics in both the AI and longevity tracks, in addition to their popular Tales from the Road entrepreneur panels. 

Take advantage of these conversations and bring these perspectives into your own fundraising journey. Super early bird rates apply until April 15, so register early to save $300!

Digital RESI June 2022 Agenda

  Tuesday
(June 7)		 Wednesday
(June 8)		 Thursday
(June 9)
10AM EDT
Innovator’s Pitch Challenge Session #1
Innovator’s Pitch Challenge Session #5
Innovator’s Pitch Challenge Session #9
11AM EDT
Beyond Big Pharma Panel
Partnering & Perspectives from Small- and Mid-Sized Biotech
AI vs. Life Science Panel
Which Comes First in Early-Stage Investment? 
Age-Tech Care Management Panel
Technology Improving the Lives of Older Adults
12PM EDT
Entrepreneur Workshop
Entrepreneur Workshop
Entrepreneur Workshop
1PM EDT
Angels Investors Panel
Explaining the Process of Engagement
Corporate VC Panel
The Changing Landscape & New Opportunities
Impact Investors Panel
More Than Financial Returns
Innovator’s Pitch Challenge Session #2
Innovator’s Pitch Challenge Session #6
Innovator’s Pitch Challenge Session #10
2PM EDT
The Neuroscience of Aging Panel
Aging Impact on the Nervous System
Asia Cross-Border Panel
Building Global Partnerships
Team, Tech, & Traction in Early-Stage AI Panel
Building Your Startup as a Triple Threat
3PM EDT
Innovator’s Pitch Challenge Session #3
Innovator’s Pitch Challenge Session #7
Software-Enabled Medical Devices
Investing at the Intersection of Digital Health and Medtech
4PM EDT
Tales from the Road: AI Innovation in Healthcare
Standing Out in a Growing Field
Tales from the Road: Age-Related Diseases
Developing Prevention & Treatments
Tales from the Road: Biotech and MedTech Innovators
Entrepreneurs on Their Fundraising Journey
5PM EDT
Innovator’s Pitch Challenge Session #4
Innovator’s Pitch Challenge Session #8
Innovator’s Pitch Challenge Session #11

Digital RESI March at-a-Glance

24 Mar

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Digital RESI March is in its final stretch, with many successful panels, workshops, and pitch sessions complementing three days full of partnering meetings. For companies and investors attending RESI, it has become a forum to build and maintain relationships, using RESI’s unique partnering platform to learn detailed information about each other that is frequently not readily available online. Whether meeting within RESI, or scheduling meetings in the weeks following, RESI provides its constituents with an opportunity to use a targeted approach to finding partners who are a fit for them.

Even with a return to in-person events, RESI attendees have shown that virtual events, or even a virtual component to events, have become a critical component of early-stage partnering. Virtual events have allowed companies and investors to expand their partnering activities, even if their schedule is too busy to allow travel. Furthermore, companies can now stretch their fundraising budgets further. There is no replacement for in-person events, and the ability to attend networking events and the connections formed there will remain an important part of any company’s fundraising journey, but virtual partnering will remain an important part in expanding a company’s reach.

The Digital RESI model would not have seen the success it has over the past couple of years without the enthusiastic support of our community. Thank you to the startups, investors, and service providers who return to RESI and add value to the early-stage ecosystem Check out our attendee breakdown from March:

If you missed Digital RESI March, do not worry! Digital RESI returns June 7-9 – Sign up today for super early bird rates and save $300!

Fundraising Bootcamps for Life Science Start-ups

24 Mar

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

For the past decade, Life Science Nation (LSN) has worked with thousands of life science start-ups on building connections with investors and strategic partnerships through the Redefining Early Stage Investments (RESI) conference series and the LSN Investor Database. LSN has developed rich insights and strategies to help early-stage founders on their fundraising campaigns and efficient partnering. It is our goal to help the community thrive by delivering a series of free fundraising bootcamps as companions to the RESI series. These bootcamps cover many of these topics:

  • Identifying your investors and building your global target list (GTL)
  • Preparing for the Innovator’s Pitch Challenge (IPC)
  • Keys to Successful Partnering
  • Branding & Messaging: From Seed to Series B

Access recordings of former fundraising bootcamps!

Digital RESI March recently featured a popular bootcamp, Branding & Messaging: From Seed to Series B. This session informs scientist-entrepreneurs on how to tell their company story through a cogent set of marketing materials to successfully bridge the gap from academia to start-up and move into the business development domain.

Stay tuned for the schedule of newest fundraising bootcamps this spring! If you’re interested in LSN’s lineup of entrepreneur education programs, please feel free to contact our business development team.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

Hot Investor Mandate: Venture Arm of Family Office Invests Globally and Broadly Across All Life Science Sectors From Seed to Series C

24 Mar

A venture arm of a family office invests in all sectors of the life sciences, looking for companies that are 2-5 years from exit. The firm invests globally, although they have a preference for companies based in the UK and in Central/Eastern Europe. The firm invests from Seed-Series C, and generally will invest $1-5M per round.

The firm is both sector and indication agnostic, and is less focused on stage of development and more focused on time to exit, looking for companies with a strategy that will allow them to exit within 2-5 years after the investment.

The firm generally does not act as a lead investor. The firm does not generally take a board seat, and is usually a silent investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based Evergreen Fund Backed by a Family Office Invests in Novel Therapeutics, Medical Devices, and Healthcare Services

24 Mar

A biotech early stage investment firm headquartered in Asia invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm in Western Europe Invests Up to €8M in Therapeutics, Devices, and Digital Health Companies With a Focus on Pre-Clinical Opportunities

24 Mar

A firm based in Western Europe invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the firm invests in companies that are revenue positive. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In the country they are headquartered in, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, the firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Public Biopharma Company Seeks Licensing Opportunities in Oncology, Ophthalmology, and Nephrology, Most Interested in US/EU Companies

24 Mar

A public biopharmaceutical company with over 20 years operation in China’s pharmaceutical industry is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm is interested in in-licensing clinical stage assets for development, while collaborative R&D can also be considered. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the US and Europe. The firm is currently looking for new opportunities globally with a focus on US and EU.

Currently, the firm is seeking therapeutics in oncology, ophthalmology, and nephrology. The firm is most interested in new formulation and is open to small molecule, biologics, biosimilars, and repurposed drugs. The firm currently focuses on assets in phase 2 clinical trials, while it can consider assets from pre-clinical to on-market stages.

The firm is seeking innovative assets that address large unmet medical need. The firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →